Elutia Inc. is a commercial-stage company, which has developed a portfolio of products using both human and porcine tissue. Its portfolio of products spans the Womenâs Health and Cardiovascular markets. In Womenâs Health, it offers SimpliDerm, a novel biological matrix that leverages the inherent science of natural healing processes. SimpliDerm's design uses human-based hydrated acellular dermal matrix (ADM), which mitigates inflammation and enhances tissue incorporation. In Cardiovascular, it sells its specialized porcine small intestine submucosa for use as an intracardiac and vascular patch, as well as for pericardial reconstruction. In addition, its TYKE product is designed for use in the neonatal patient population. It is focused on advancing NXT-41x, a biomatrix that directly addresses the root causes of reconstruction infections following mastectomy. NXT-41x combines biologics and extended antibiotic release to provide protection while supporting tissue regeneration.
äŒæ¥ã³ãŒãELUT
äŒç€ŸåElutia Inc
äžå Žæ¥Oct 08, 2020
æé«çµå¶è²¬ä»»è
ãCEOãMills (C. Randal)
åŸæ¥å¡æ°51
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Oct 08
æ¬ç€Ÿæåšå°12510 Prosperity Drive
éœåžSILVER SPRING
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·20904
é»è©±çªå·12402471143
ãŠã§ããµã€ãhttps://elutia.com/
äŒæ¥ã³ãŒãELUT
äžå Žæ¥Oct 08, 2020
æé«çµå¶è²¬ä»»è
ãCEOãMills (C. Randal)
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã